US Influenza Testing Market Outlook 2031 Growth Drivers and Emerging Diagnostic Technologies
The global Influenza Diagnostics Market is witnessing steady growth as increasing influenza prevalence, rising public awareness, government initiatives, and advancements in diagnostic technologies drive demand for effective disease detection. The market size is expected to reach US$ 2.3 billion by 2031, registering a compound annual growth rate (CAGR) of 6.7% during 2025–2031. The growing need for timely influenza identification, particularly among vulnerable populations, is encouraging healthcare providers and diagnostic laboratories to adopt advanced testing solutions. Increasing demand for accurate diagnostic procedures and improved healthcare preparedness is further contributing to the expansion of the global market.
According to The Insight Partners, the Influenza Diagnostics Market Size was valued at US$ 1.46 billion in 2024. The market is expected to experience consistent growth through 2031, supported by increasing influenza cases, technological advancements, and expanding diagnostic capabilities. The market assessment covers molecular diagnostic tests and traditional diagnostic tests, along with applications across reference laboratories, hospitals, clinical laboratories, and other end users.
Download Sample PDF: https://www.theinsightpartners.com/sample/TIPBT00002215
Influenza Diagnostics Market Overview and Growth Drivers
Influenza diagnostics play an important role in identifying influenza virus infections and supporting appropriate healthcare management. Accurate and timely diagnosis enables healthcare professionals to identify infected individuals and make informed decisions regarding patient care. As influenza continues to affect populations worldwide, the demand for reliable diagnostic solutions is increasing across healthcare facilities.
One of the major factors supporting market growth is the increasing prevalence of influenza. A rising number of influenza cases creates demand for diagnostic procedures that help healthcare professionals detect infections. According to information highlighted in The Insight Partners report, the Centers for Disease Control and Prevention stated that 9 million patients were affected by influenza in 2021. Additionally, WHO GISRS laboratories tested more than 490,516 samples during 2021–2022, according to February 2021 updates referenced in the report.
Public awareness and government initiatives are also contributing to the growth of the Influenza Diagnostics Market. Government-sponsored healthcare awareness campaigns emphasize the importance of early detection and appropriate medical attention. As awareness increases, more individuals recognize the importance of diagnostic testing, supporting demand for influenza detection solutions.
The increasing geriatric population represents another important growth driver. Older adults are more susceptible to complications associated with influenza, creating a greater need for diagnostic testing and healthcare management. These factors are encouraging healthcare providers to strengthen their diagnostic capabilities.
Technological Advancements Transforming Influenza Diagnostics
Technological developments are creating new opportunities in the Influenza Diagnostics Market. Advanced detection technologies, including next-generation sequencing and genomic technologies, are expected to support improvements in diagnostic sensitivity and specificity. These approaches can help identify specific influenza viruses more effectively and support healthcare professionals in making informed treatment decisions.
The development of modular diagnostic platforms is another emerging trend. Adaptable diagnostic solutions can help healthcare systems respond to changing influenza strains and other respiratory virus threats. Greater flexibility in diagnostic platforms may support faster adjustments to evolving healthcare requirements.
Artificial intelligence and machine learning are also emerging as potential opportunities for the industry. These technologies can support the analysis of large datasets, identification of patterns, and prediction of potential outbreaks. Their integration into diagnostic processes may contribute to improved accuracy and faster results.
Influenza Diagnostics Market Segmentation Analysis
Based on type, the Influenza Diagnostics Market is segmented into molecular diagnostic tests and traditional diagnostic tests.
Molecular Diagnostic Tests: Molecular diagnostic tests represent an important segment of the market. These testing approaches support the identification of influenza viruses through molecular-level detection techniques. The report identifies molecular diagnostic tests as the leading type segment in terms of revenue in 2023. Growing interest in advanced detection technologies is supporting the importance of this segment.
Traditional Diagnostic Tests: Traditional diagnostic tests also contribute to the market by providing established approaches for influenza detection. Their inclusion in the market reflects the continuing demand for different diagnostic methods across healthcare facilities and testing environments.
Based on end user, the market is divided into reference laboratories, hospitals and clinical laboratories, and other end users.
Reference laboratories contribute to market demand through their diagnostic testing activities. Hospitals and clinical laboratories represent important end users because they support patient diagnosis and healthcare delivery. Other end users further expand the application landscape of influenza diagnostic solutions.
Regional Outlook of the Influenza Diagnostics Market:
The global Influenza Diagnostics Market covers North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa.
North America represented the dominant regional market in 2023. The United States is a key country within the region, supported by increasing influenza prevalence, public awareness, government initiatives, and an expanding geriatric population.
Europe represents another important market, with the report covering countries such as the United Kingdom, Germany, France, Russia, and Italy. Asia Pacific includes China, India, Japan, and Australia, while South and Central America covers Brazil and Argentina. The Middle East and Africa market includes South Africa, Saudi Arabia, and the United Arab Emirates. The report also identifies Asia Pacific as an important region for future market growth, highlighting its potential within the global influenza diagnostics landscape.
Emerging Opportunities in the Influenza Diagnostics Market
Rapid and point-of-care testing represents a significant opportunity for market participants. These diagnostic solutions can support faster influenza detection in clinics, emergency rooms, and other healthcare settings. Faster testing may help healthcare providers make timely treatment decisions and minimize the potential spread of infection.
Multiplex assay development is another promising opportunity. These diagnostic approaches can simultaneously detect multiple respiratory pathogens, including different influenza subtypes. This capability may improve testing efficiency and support the assessment of patients experiencing respiratory illness.
Furthermore, artificial intelligence integration offers opportunities to strengthen diagnostic processes through improved data analysis, pattern identification, and outbreak prediction. Companies investing in advanced diagnostic technologies and adaptable testing platforms may benefit from these emerging opportunities.
Top Key Players in the Influenza Diagnostics Market
The major companies operating in the Influenza Diagnostics Market include:
- Abbott
- Quidel Corporation
- bioMérieux
- BD
- F. Hoffmann-La Roche Ltd
- Oxford Biosystems
- Thermo Fisher Scientific
- Meridian Bioscience
- Cepheid
- altona Diagnostics GmbH
These companies are profiled in the market report, which examines the competitive landscape and industry developments.
Future outlook:
The Influenza Diagnostics Market is expected to maintain steady growth through 2031, reaching US$ 2.3 billion at a CAGR of 6.7% during 2025–2031. Increasing influenza prevalence, greater public awareness, government initiatives, and the growing geriatric population are important factors supporting market expansion. Meanwhile, rapid point-of-care testing, multiplex assays, artificial intelligence, and advanced detection technologies are creating additional opportunities. As healthcare providers continue to emphasize timely and accurate influenza detection, diagnostic technologies are expected to remain an important part of global healthcare preparedness.
Trending Reports:
· Medical Second Opinion Market Growth and Forecast by 2031
· Blood Filter Market Growth and Recent Trends by 2028
· Brain Implants Market Dynamics and Developments by 2030
About Us:
The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials.
Contact Us:
Contact Person: Ankit Mathur
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876
Also Available in : Korean|German|Japanese|French|Chinese|Italian|Spanish
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- Games
- Gardening
- Health
- Home
- Literature
- Music
- Networking
- Other
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness